215 related articles for article (PubMed ID: 16118736)
1. [Rheumatoid arthritis: early aggressive therapy including biologicals -- pro].
Rubbert-Roth A
Dtsch Med Wochenschr; 2005 Aug; 130(33):1900. PubMed ID: 16118736
[No Abstract] [Full Text] [Related]
2. [Biologicals are the first choice for RA treatment -- contra].
Krüger K
Dtsch Med Wochenschr; 2005 Aug; 130(33):1901. PubMed ID: 16118737
[No Abstract] [Full Text] [Related]
3. [Rheumatoid arthritis: milestones in classification and treatment].
Fiehn C
Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
[TBL] [Abstract][Full Text] [Related]
4. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
Mulherin D; Sheeran TP
Arthritis Rheum; 2003 Mar; 48(3):868. PubMed ID: 12632461
[No Abstract] [Full Text] [Related]
5. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
6. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
7. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.
Buch MH; Marzo-Ortega H; Bingham SJ; Emery P
Rheumatology (Oxford); 2004 Feb; 43(2):243-4. PubMed ID: 14739466
[No Abstract] [Full Text] [Related]
8. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
9. Use of biologic agents in rheumatoid arthritis: introduction.
Silman AJ
Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv3-4. PubMed ID: 21859703
[No Abstract] [Full Text] [Related]
10. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
11. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
Yen JH
Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
[TBL] [Abstract][Full Text] [Related]
12. [Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
Takeuchi T
Nihon Rinsho; 2005 Jan; 63 Suppl 1():444-7. PubMed ID: 15799396
[No Abstract] [Full Text] [Related]
13. Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis.
Franklin G; Greenspan J; Chen S
Ann Clin Lab Sci; 2009; 39(2):192-5. PubMed ID: 19429808
[TBL] [Abstract][Full Text] [Related]
14. Joint approach.
Palmer K
Minn Med; 2009 Sep; 92(9):22-5. PubMed ID: 19877473
[No Abstract] [Full Text] [Related]
15. Rituximab (Rituxan) for rheumatoid arthritis.
Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
[No Abstract] [Full Text] [Related]
16. [Non-TNF biologicals in therapy].
Wollenhaupt J; Burmester GR
Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
[No Abstract] [Full Text] [Related]
17. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
Kavanaugh A
Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
[No Abstract] [Full Text] [Related]
18. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
19. [Focusing on the use of biologics in rheumatoid arthritis].
Devauchelle-Pensec V; Guellec D
Rev Prat; 2015 May; 65(5):687-8. PubMed ID: 26165113
[No Abstract] [Full Text] [Related]
20. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A; Cohen S; Cush JJ
J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
[No Abstract] [Full Text] [Related]
[Next] [New Search]
